{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:37:15Z","timestamp":1794494235242,"version":"4.9.1"},"reference-count":47,"publisher":"American Association for Cancer Research (AACR)","issue":"3","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"HHS | NIH | NCI | CCR | National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA261987"],"award-info":[{"award-number":["R37CA261987"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | NCI | CCR | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA285446"],"award-info":[{"award-number":["R01CA285446"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["OC170228, OC200302, OC200225"],"award-info":[{"award-number":["OC170228, OC200302, OC200225"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-20-1-0617 BC191031"],"award-info":[{"award-number":["W81XWH-20-1-0617 BC191031"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"HERA Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100009141","name":"Cancer League of Colorado","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | NCI | CCR | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA046934"],"award-info":[{"award-number":["P30CA046934"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>High-grade serous carcinoma (HGSC) of the fallopian tube, ovary, and peritoneum is the most common type of ovarian cancer and is predicted to be immunogenic because the presence of tumor-infiltrating lymphocytes conveys a better prognosis. However, the efficacy of immunotherapies has been limited because of the immune-suppressed tumor microenvironment (TME). Tumor metabolism and immune-suppressive metabolites directly affect immune cell function through the depletion of nutrients and activation of immune-suppressive transcriptional programs. Tryptophan (TRP) catabolism is a contributor to HGSC disease progression. Two structurally distinct rate-limiting TRP catabolizing enzymes, indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase 2 (TDO2), evolved separately to catabolize TRP. IDO1\/TDO2 are aberrantly expressed in carcinomas and metabolize TRP into the immune-suppressive metabolite kynurenine (KYN), which can engage the aryl hydrocarbon receptor to drive immunosuppressive transcriptional programs. To date, IDO inhibitors tested in clinical trials have had limited efficacy, but those inhibitors did not target TDO2, and we find that HGSC cell lines and clinical outcomes are more dependent on TDO2 than IDO1. To identify inflammatory HGSC cancers with poor prognosis, we stratified patient ascites samples by IL6 status, which correlates with poor prognosis. Metabolomics revealed that IL6-high patient samples had enriched KYN. TDO2 knockdown significantly inhibited HGSC growth and TRP catabolism. The orally available dual IDO1\/TDO2 inhibitor, AT-0174, significantly inhibited tumor progression, reduced tumor-associated macrophages, and reduced expression of immune-suppressive proteins on immune and tumor cells. These studies demonstrate the importance of TDO2 and the therapeutic potential of AT-0174 to overcome an immune-suppressed TME.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Developing strategies to improve response to chemotherapy is essential to extending disease-free intervals for patients with HGSC of the fallopian tube, ovary, and peritoneum. In this article, we demonstrate that targeting TRP catabolism, particularly with dual inhibition of TDO2 and IDO1, attenuates the immune-suppressive microenvironment and, when combined with chemotherapy, extends survival compared with chemotherapy alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0513","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T12:26:16Z","timestamp":1709814376000},"page":"822-833","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2790-7780","authenticated-orcid":true,"given":"Lyndsey S.","family":"Crump","sequence":"first","affiliation":[{"name":"1Department of Pathology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-6245","authenticated-orcid":true,"given":"Jessica L.","family":"Floyd","sequence":"additional","affiliation":[{"name":"2Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1135-8740","authenticated-orcid":true,"given":"Li-Wei","family":"Kuo","sequence":"additional","affiliation":[{"name":"1Department of Pathology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-8247","authenticated-orcid":true,"given":"Miriam D.","family":"Post","sequence":"additional","affiliation":[{"name":"1Department of Pathology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1415-4200","authenticated-orcid":true,"given":"Mike","family":"Bickerdike","sequence":"additional","affiliation":[{"name":"3Antido Therapeutics, Melbourne, Australia."},{"name":"4BioTarget Consulting, Auckland, New Zealand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7681-2863","authenticated-orcid":true,"given":"Kathleen","family":"O'Neill","sequence":"additional","affiliation":[{"name":"1Department of Pathology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8126-1410","authenticated-orcid":true,"given":"Kayla","family":"Sompel","sequence":"additional","affiliation":[{"name":"5Division of Reproductive Sciences Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8380-7157","authenticated-orcid":true,"given":"Kimberly R.","family":"Jordan","sequence":"additional","affiliation":[{"name":"6Department of Immunology and Microbiology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6608-2585","authenticated-orcid":true,"given":"Bradley R.","family":"Corr","sequence":"additional","affiliation":[{"name":"2Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9963-5943","authenticated-orcid":true,"given":"Nicole","family":"Marjon","sequence":"additional","affiliation":[{"name":"2Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0237-7453","authenticated-orcid":true,"given":"Elizabeth R.","family":"Woodruff","sequence":"additional","affiliation":[{"name":"5Division of Reproductive Sciences Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9960-0991","authenticated-orcid":true,"given":"Jennifer K.","family":"Richer","sequence":"additional","affiliation":[{"name":"1Department of Pathology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5809-5271","authenticated-orcid":true,"given":"Benjamin G.","family":"Bitler","sequence":"additional","affiliation":[{"name":"5Division of Reproductive Sciences Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"2024031814012489900_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2024031814012489900_bib2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2024031814012489900_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2024031814012489900_bib4","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol"},{"key":"2024031814012489900_bib5","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nat Commun"},{"key":"2024031814012489900_bib6","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ygyno.2017.10.003","article-title":"PARP inhibitors: clinical utility and possibilities of overcoming resistance","volume":"147","author":"Bitler","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2024031814012489900_bib7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11864-018-0584-3","article-title":"Review of immune therapies targeting ovarian cancer","volume":"19","author":"Fan","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"2024031814012489900_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bpobgyn.2019.03.005","article-title":"Immunotherapy of gynecological cancers","volume":"60","author":"Matanes","year":"2019","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2024031814012489900_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/1471-2407-11-210","article-title":"Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients","volume":"11","author":"Lane","year":"2011","journal-title":"BMC Cancer"},{"key":"2024031814012489900_bib10","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1038\/s41467-020-17750-z","article-title":"Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine","volume":"11","author":"Campesato","year":"2020","journal-title":"Nat Commun"},{"key":"2024031814012489900_bib11","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41467-023-37170-z","article-title":"Quinolinate promotes macrophage-induced immune tolerance in glioblastoma through the NMDAR\/PPARgamma signaling axis","volume":"14","author":"Kesarwani","year":"2023","journal-title":"Nat Commun"},{"key":"2024031814012489900_bib12","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/2159-8290.CD-21-0680","article-title":"Synthetic essentiality of tryptophan 2,3-dioxygenase 2 in APC-mutated colorectal cancer","volume":"12","author":"Lee","year":"2022","journal-title":"Cancer Discov"},{"key":"2024031814012489900_bib13","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1038\/s41467-022-33285-x","article-title":"USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer","volume":"13","author":"Shi","year":"2022","journal-title":"Nat Commun"},{"key":"2024031814012489900_bib14","first-page":"165","article-title":"Chapter Five \u2013 Tryptophan in health and disease","volume-title":"Advances in clinical chemistry","author":"Comai","year":"2020"},{"key":"2024031814012489900_bib15","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1158\/1078-0432.CCR-20-1762","article-title":"The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval","volume":"26","author":"Jordan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2024031814012489900_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/toxsci\/kfq024","article-title":"Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling","volume":"115","author":"DiNatale","year":"2010","journal-title":"Toxicol Sci"},{"key":"2024031814012489900_bib17","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.3389\/fimmu.2018.02033","article-title":"Aryl hydrocarbon receptor promotes IL-10 expression in inflammatory macrophages through src-STAT3 signaling pathway","volume":"9","author":"Zhu","year":"2018","journal-title":"Front Immunol"},{"key":"2024031814012489900_bib18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-021-01080-8","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy","volume":"14","author":"Tang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2024031814012489900_bib19","first-page":"1","article-title":"Tryptophan catabolism in epithelial ovarian carcinoma","volume":"14","author":"Smith","year":"2019","journal-title":"Trends Cancer Res"},{"key":"2024031814012489900_bib20","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41591-019-0404-8","article-title":"The landscape of cancer cell line metabolism","volume":"25","author":"Li","year":"2019","journal-title":"Nat Med"},{"key":"2024031814012489900_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40170-023-00307-1","article-title":"Dual inhibition of IDO1\/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer","volume":"11","author":"Wu","year":"2023","journal-title":"Cancer Metab"},{"key":"2024031814012489900_bib22","doi-asserted-by":"crossref","first-page":"P196","DOI":"10.1186\/2051-1426-2-S3-P196","article-title":"Preclinical assessment of a novel small molecule inhibitor of tryptophan 2,3-dioxygenase 2 (TDO2)","volume":"2","author":"Crosignani","year":"2014","journal-title":"J Immunother Cancer"},{"key":"2024031814012489900_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.3794","article-title":"Determination of epacadostat, a novel IDO1 inhibitor in mouse plasma by LC-MS\/MS and its application to a pharmacokinetic study in mice","volume":"31","author":"Dhiman","year":"2017","journal-title":"Biomed Chromatogr"},{"key":"2024031814012489900_bib24","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/mc.23064","article-title":"Activation of Wnt signaling promotes olaparib resistant ovarian cancer","volume":"58","author":"Yamamoto","year":"2019","journal-title":"Mol Carcinog"},{"key":"2024031814012489900_bib25","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.isci.2019.07.049","article-title":"Multi-omic approaches identify metabolic and autophagy regulators important in ovarian cancer dissemination","volume":"19","author":"Wheeler","year":"2019","journal-title":"iScience"},{"key":"2024031814012489900_bib26","doi-asserted-by":"crossref","first-page":"e9757","DOI":"10.15252\/msb.20209757","article-title":"The cancer dependency map enables drug mechanism-of-action investigations","volume":"16","author":"Vazquez","year":"2020","journal-title":"Mol Syst Biol"},{"key":"2024031814012489900_bib27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"2024031814012489900_bib28","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1111\/trf.14623","article-title":"Metabolomics evaluation of early-storage red blood cell rejuvenation at 4 degrees C and 37 degrees C","volume":"58","author":"Gehrke","year":"2018","journal-title":"Transfusion"},{"key":"2024031814012489900_bib29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1158\/1541-7786.MCR-18-0362","article-title":"A role for tryptophan-2,3-dioxygenase in CD8 T-cell suppression and evidence of tryptophan catabolism in breast cancer patient plasma","volume":"17","author":"Greene","year":"2019","journal-title":"Mol Cancer Res"},{"key":"2024031814012489900_bib30","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/0008-5472.CAN-16-1272","article-title":"CRISPR\/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma","volume":"76","author":"Walton","year":"2016","journal-title":"Cancer Res"},{"key":"2024031814012489900_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-22-0102","article-title":"ATF6-mediated signaling contributes to PARP inhibitor resistance in ovarian cancer","volume":"21","author":"McMellen","year":"2022","journal-title":"Mol Cancer Res"},{"key":"2024031814012489900_bib32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/cas.15182","article-title":"Stemness and immune evasion conferred by the TDO2-AHR pathway are associated with liver metastasis of colon cancer","volume":"113","author":"Miyazaki","year":"2022","journal-title":"Cancer Sci"},{"key":"2024031814012489900_bib33","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1038\/s41388-018-0581-9","article-title":"Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles","volume":"38","author":"Grabosch","year":"2019","journal-title":"Oncogene"},{"key":"2024031814012489900_bib34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1158\/1541-7786.MCR-19-0239","article-title":"Targeting the kynurenine pathway for the treatment of cisplatin-resistant lung cancer","volume":"18","author":"Nguyen","year":"2020","journal-title":"Mol Cancer Res"},{"key":"2024031814012489900_bib35","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"2024031814012489900_bib36","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024031814012489900_bib37","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024031814012489900_bib38","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","article-title":"Metabolic programming and immune suppression in the tumor microenvironment","volume":"41","author":"Arner","year":"2023","journal-title":"Cancer Cell"},{"key":"2024031814012489900_bib39","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccell.2022.12.008","article-title":"Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"key":"2024031814012489900_bib40","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ygyno.2017.07.005","article-title":"A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer","volume":"146","author":"Kristeleit","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2024031814012489900_bib41","doi-asserted-by":"crossref","first-page":"e000870","DOI":"10.1136\/jitc-2020-000870","article-title":"Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors","volume":"8","author":"Naing","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2024031814012489900_bib42","doi-asserted-by":"crossref","first-page":"678999","DOI":"10.3389\/fimmu.2021.678999","article-title":"IDO1 expression in ovarian cancer induces PD-1 in T cells via aryl hydrocarbon receptor activation","volume":"12","author":"Amobi-McCloud","year":"2021","journal-title":"Front Immunol"},{"key":"2024031814012489900_bib43","doi-asserted-by":"crossref","first-page":"eabg8402","DOI":"10.1126\/scitranslmed.abg8402","article-title":"Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses","volume":"14","author":"Odunsi","year":"2022","journal-title":"Sci Transl Med"},{"key":"2024031814012489900_bib44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/cells9010051","article-title":"Distinct role of CD11b(+)Ly6G(\u2212)Ly6C(\u2212) myeloid-derived cells on the progression of the primary tumor and therapy-associated recurrent brain tumor","volume":"9","author":"Wu","year":"2019","journal-title":"Cells"},{"key":"2024031814012489900_bib45","doi-asserted-by":"crossref","first-page":"e20191869","DOI":"10.1084\/jem.20191869","article-title":"Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer","volume":"217","author":"Etzerodt","year":"2020","journal-title":"J Exp Med"},{"key":"2024031814012489900_bib46","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neo.2017.12.002","article-title":"A longitudinal analysis of IDO and PDL1 expression during immune- or targeted therapy in advanced melanoma","volume":"20","author":"Kr\u00e4henb\u00fchl","year":"2018","journal-title":"Neoplasia"},{"key":"2024031814012489900_bib47","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/s41591-021-01544-x","article-title":"A phase 1\/2 trial of an immune-modulatory vaccine against IDO\/PD-L1 in combination with nivolumab in metastatic melanoma","volume":"27","author":"Kjeldsen","year":"2021","journal-title":"Nat Med"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0513\/3422238\/crc-23-0513.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/3\/822\/3423229\/crc-23-0513.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/3\/822\/3423229\/crc-23-0513.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T10:02:15Z","timestamp":1710756135000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/3\/822\/735165\/Targeting-Tryptophan-Catabolism-in-Ovarian-Cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,18]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0513","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.25429245","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429254.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429257","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429215","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429227","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429239","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429260.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429245.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429251","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429221","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429233","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429248.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429212.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429209.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429215.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429209","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429257.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429251.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429230.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429212","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429224","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429248","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429224.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429218","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429218.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429260","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429221.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429227.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429230","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429242","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429254","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429242.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429233.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25429239.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7126521","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.7126521.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]}}}